Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2019-07, Vol.94 (7), p.E183-E185
Hauptverfasser:	Quinquenel, Anne, Godet, Sophie, Dartigeas, Caroline, Ysebaert, Loïc, Dupuis, Jehan, Ohanyan, Haykanush, Collignon, Aude, Gilardin, Laurent, Lepretre, Stéphane, Dilhuydy, Marie‐Sarah, Vignon, Marguerite, Guibert, Sophie, Dmytruk, Natalia, Durot, Eric, Ghez, David, Roos Weil, Damien, Béné, Marie‐Christine, Toussaint, Elise, Merabet, Fatiha, Lévy, Vincent, Delmer, Alain, Aurran, Thérèse
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmune Diseases - drug therapy Autoimmune Diseases - mortality Chronic lymphocytic leukemia Cytopenia Disease-Free Survival Female Hematologic Diseases - drug therapy Hematologic Diseases - mortality Hematology Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Purines - administration & dosage Pyrazoles - administration & dosage Pyrimidines - administration & dosage Quinazolinones - administration & dosage Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!